U.S. markets closed

Bayer Aktiengesellschaft (BAYRY)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
15.73-0.24 (-1.47%)
At close: 3:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close15.97
Open15.77
Bid0.00 x 0
Ask0.00 x 0
Day's Range15.64 - 15.78
52 Week Range11.65 - 21.05
Volume217,574
Avg. Volume384,271
Market Cap62.137B
Beta (5Y Monthly)1.30
PE Ratio (TTM)N/A
EPS (TTM)-3.05
Earnings DateN/A
Forward Dividend & Yield0.59 (3.70%)
Ex-Dividend DateApr 28, 2021
1y Target Est17.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Bayer's Cell, Gene Therapies for Parkinson's Disease Enters Human Trials
    Benzinga

    Bayer's Cell, Gene Therapies for Parkinson's Disease Enters Human Trials

    Bayer AG’s (OTC: BAYRY) Parkinson’s disease stem cell therapy has officially landed in the clinic, while another treatment for the neurodegenerative movement disorder is recruiting patients. Bayer’s subsidiary BlueRock Therapeutics’s trial will eventually enroll 10 participants. Patients will have dopamine-producing cells surgically implanted into a part of the brain called the putamen. The trial will primarily examine the safety and tolerability of DA01 cell transplantation a year after the pro

  • Novartis (NVS) Posts Positive Data on Kidney Disease Candidate
    Zacks

    Novartis (NVS) Posts Positive Data on Kidney Disease Candidate

    Novartis' (NVS) rare kidney disease candidate meets its primary goal in a phase II study.

  • Bayer Buys Two Biotech Firms to Beef Up Radiopharmaceuticals
    Benzinga

    Bayer Buys Two Biotech Firms to Beef Up Radiopharmaceuticals

    Bayer AG (OTC: BAYRY) will acquire two small biotech companies in a deal that adds an experimental prostate cancer medicine to the German drugmaker's pipeline. Bayer will pay an undisclosed sum for Noria Therapeutics and PSMA Therapeutics, built around radiotherapy research from the Weill Cornell Medical College in NYC. The deal is centered around an actinium-225 labeled prostate-specific membrane antigen (PSMA) small molecule currently in pre-IND studies for prostate cancer. Bayer has its portf